YPrime IRT in Action: A 4-Week Vaccine Trial Launch

A leading pharmaceutical sponsor required a highly accelerated IRT launch for a Phase 2/3 vaccine clinical trial, supporting over 8,000 participants across nearly 50 research sites, all while ensuring the highest quality.

YPrime delivered our industry-leading IRT solution in less than four weeks from contract signing to go-live. The system provided complete randomization, drug accountability, supply management, and clinical system integration capabilities for this important vaccine trial.

The success demonstrated how the right IRT technology can meet aggressive timelines. YPrime’s configurable platform enabled the study team to effectively manage patient randomization and drug supply across all sites with full regulatory adherence.

Key Takeaways

Discover how YPrime deployed and validated a complete IRT solution in under four weeks for an urgent Phase 2/3 vaccine trial

See how the platform streamlined randomization and supply management for 8,000+ participants in a two-visit study design

Learn about the automated inventory optimization that kept sites supplied during accelerated timelines

Explore how real-time metrics and reporting enabled rapid, data-driven decisions throughout the study

Get the Complete Case Study

Complete the form to learn how YPrime IRT can meet your most demanding study timelines without compromising quality.